Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 15/20 | 0.76 |
| ▸ | HDAC1 | Q13547 | 9/20 | 0.68 |
| ▸ | HDAC3 | O15379 | 4/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15397935 | 0.88 | HDAC2 (0.76) | HDAC2HDAC1HDAC3 | |
| SCHEMBL12933378 | 0.83 | HDAC2 (0.93) | HDAC2HDAC1HDAC3 | |
| SCHEMBL20788518 | 0.82 | ABCB1 (0.61) | HDAC2 | |
| SCHEMBL16380794 | 0.82 | HDAC2 (1.00) | HDAC2HDAC1HDAC3 | |
| Dimethylamine SCHEMBL1067124 | 0.81 | HDAC2 (0.88) | HDAC2HDAC1HDAC3 | |
| SCHEMBL12933399 | 0.80 | HDAC2 (0.87) | HDAC2HDAC1HDAC3 | |
| SCHEMBL15397970 | 0.79 | HDAC2 (0.86) | HDAC2HDAC1HDAC3 | |
| SCHEMBL1066024 | 0.78 | HDAC2 (0.83) | HDAC2HDAC1HDAC3 | |
| SCHEMBL15398027 | 0.77 | HDAC2 (1.00) | HDAC2HDAC1HDAC3 | |
| SCHEMBL15398014 | 0.77 | HDAC2 (0.83) | HDAC2HDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190076552-A1 | Precursor of a histone deacetylase inhibitor PET imaging compound for tracking cerebral neurodegenerative and tumor diseases | INSTITUTE OF NUCLEAR ENERGY RESEARCH, NUCLEAR ENERGY COUNCIL, EXECUTIVE YUAN (TW) | 2019-03-14 | — | — | US | claimed |
| US-10507250-B2 | Precursor of a histone deacetylase inhibitor PET imaging compound for tracking cerebral neurodegenerative and tumor diseases | INSTITUTE OF NUCLEAR ENERGY RESEARCH, ATOMIC ENERGY COUNCIL, EXECUTIVE YUAN (TW) | 2019-12-17 | — | — | US | disclosed |
| US-20190076552-A1 | Precursor of a histone deacetylase inhibitor PET imaging compound for tracking cerebral neurodegenerative and tumor diseases | INSTITUTE OF NUCLEAR ENERGY RESEARCH, NUCLEAR ENERGY COUNCIL, EXECUTIVE YUAN (TW) | 2019-03-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10507250-B2 | Precursor of a histone deacetylase inhibitor PET imaging compound for tracking cerebral neurodegenerative and tumor diseases | H1-3, H1-2, HDAC2 | HDAC2 3/4885HDAC1 6/4885HDAC3 15/4885 |
| US-20190076552-A1 | Precursor of a histone deacetylase inhibitor PET imaging compound for tracking cerebral neurodegenerative and tumor diseases | H1-3, H1-2, HDAC2 | HDAC2 3/4885HDAC1 6/4885HDAC3 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.